SCIENTIFIC EVENTS
3Rs implementation in veterinary vaccine batchrelease
testing: Current state-of-the-art and future opportunities
Europe & Americas Webinar
October 6, 2022
3Rs implementation in veterinary vaccine batch-release
testing: Current state-of-the-art and future opportunities
Asia Webinar
October 20, 2022
8th Annual IABS Statistics Workshop – Advancing the Impact of CMC Statistics for a New Generation of Statisticians, Scientists, and Modelers
November 7-10, 2022
3Rs implementation in veterinary vaccine batch-release testing: Current state-of-the-art and future opportunities
ff
November 16, 2022
Brussels, Belgium
Globally Harmonized Specifications: Current State and Future Opportunities
A Hybrid Meeting
Meeting rescheduled
New Date : January 10-12, 2023
Basel, Switzerland
Maintening the Quality of Vaccines through the Use of References Standards Current Challenges and Future Opportunities
June 21-22, 2023
NEWS
What does IABS do that is unique ?
In this short interview, Joris Vandeputte, President of IABS has answered the question “What does IABS do that is unique ?”
To learn more about the International Alliance for Biological…
ZAPI Stakeholder Conference Report
We are pleased to let you know that the Zoonoses Anticipation and Preparedness Initiative (ZAPI) Stakeholders Conference Report (February 4 & 5, 2021) is now available.
IABS wishes a Happy and Health New Year 2022 to all
IABS wishes a Happy and Health New Year 2022 to all. To learn more about the upcoming conference :
IABS COLLABORATIONS
INNOVATIVE MEDICINES INITIATIVE (IMI) PROJECTS :
IMI is a European public-private partnership aiming to speed up the development of better and safer medicines. IMI is partly founded by the European Commission.
The IABS European Affiliate (IABS-EU) was part of consortia which have been selected by IMI to be the public partners of following consortia.
IABS-EU was selected to drive the regulatory part of those consortia.
IABS COLLABORATIONS / MANCO, A EUROPEAN COMMISSION PROJECT :
MANCO (Monclonal Antibodies against COVID-19) is one of the eighteen projects that have been successfully selected by the European Commission, which is devoted to the development of Monoclonal Antibodies agains COVID-19.
IABES-EU was selected to drive the regulatory part of the project
TESTIMONIALS
Paul Henri Lambert
Professor at University of Geneva
Founder of ADVAC
“I have appreciated the achievements of IABS since many years. It is a unique independent organization that can…
John Petricciani
Past President
Advisor to the Board
“ Cell substrates have been a key element in the evolution of biological products since the…
Kathryn Zoon
“ As a long term US regulator and scientist, I have been working with IABS for many years. The IABS has …
Philippe Duclos
Director ADVAC
University of Geneva
“ A vibrant organization that allows dialogue beyond professional boundaries…
